Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Octreotide is used to decrease portal pressure of cirrhotic patients admitted for variceal bleeding. When patients are in haemorrhagic shock, the recommended drug to increase arterial pressure is norepinephrine. Microcirculatory effects of octreotide when it is added to noradrenaline has not been investigated yet. The aim of the study is to evaluate the effect of octreotide plus norepinephrine for patient with haemorrhagic shock after variceal bleeding.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire, Amiens
• Treatments: Norepinephrine; Octreotide

Criteria

Inclusion Criteria:

• patients more than 18 years old

• patient with liver cirrhosis

• patient with haemorrhagic shock due to variceal bleeding

• patient with an arterial blood pressure less than 65 mmHg despite

• patient able to express consent

• signed written informed consent form

• patient covered by national health insurance

Exclusion Criteria:

• patient less than 18 years old

• patient non covered by national health insurance

• pregnant or breast feeding patent

• known octreotide allergy

• cardiac arrest because of shock

• refused consent